![]() VIARTIS
|
||||||
PARKINSON'S DISEASE |
||||||
|
||||||
|
PARKINSON'S DISEASE NEWS
|
|
||||
NOVEMBER 2012
29th November 2012 - News release PIMAVANSERIN CLINICAL TRIAL RESULTS
In the clinical trial patients took either 40 mg of Pimavanserin or a placebo once a day for six weeks. Patients also received stable doses of their existing Parkinson’s Disease treatments throughout the study. Those people taking Pimavanserin reduced their score on the SAPS-PD scale by 5.79. Those people taking a placebo reduced their score by 2.73. Although the results were described as "representing a highly significant and clinically meaningful treatment" the effects of Pimavanserin were quite moderate when compared to those taking a placebo. Half the effect of Pimavanserin was achieved by effectively taking nothing at all. The study also fails to assess the long term effects of Pimavanserin as it lasted only 43 days. All drugs, due to a process called "feedback inhibition" end up reducing their over time. The most common adverse events were urinary tract infection and falls, but these were at a rate very little more than for those taking a placebo. Most symptoms of psychosis in Parkinson's Disease are due to Parkinson's Disease drugs themselves. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
28th November 2012 - New book UNSHAKEN FAITH Machele Coleman Bess
10th November 2012 - News release A FUTURE REPLACEMENT FOR SINEMET Depomed are developing a new drug called DM-1992 that could outperform Sinemet in the treatment of Parkinson's Disease. Just like Sinemet, DM-1992 is a combination of L-dopa and carbidopa, which prevents the breakdown of L-dopa. DM-1992 also includes AcuForm, which makes use of the properties of certain polymers. These polymers have long been used to "fluff" ice cream and are safe to use. Upon entering the stomach an AcuForm coated pill expands and is retained in the stomach for up to 8 hours. For more information go to Depomed. AcuForm helps to deliver a drug like Sinemet over a longer period of time. Depomed's formulation was able to extend the therapeutic duration of L-dopa to nine hours, compared to Sinemet CR's seven hours. The time to reach peak blood levels was extended to four hours compared to 2 hours for Sinemet CR. This could enable a decrease in the dosage of L-dopa, and the ridding of side effects such as nausea and dyskinesia. In a recent clinical trial, DM-1992 reduced off time from 5.4 hours per day to 4.5 hours per day. DM-1992 was generally well tolerated, and there were no serious adverse events. For the news release click here. For a printable version of this article click here. In order to refer to this article on its own click here.
8th November 2012 - New book NAVIGATING LIFE WITH PARKINSON DISEASE Sotirios Parashos (Author), Rosemary Wichmann (Author), Todd Melby (Contributor)
|
||||||
![]() |
||||||
©2006-2012 Viartis | ||||||
[email protected] |